The US Food and Drug Administration has recently approved several new glucagon-like peptide-1 (GLP-1) agonists alone and in combination with various insulin products. The second of 2 articles in a series, this review will describe the potential advantages and disadvantages of the GLP-1 agonist class of products.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjmed.2018.05.043 | DOI Listing |
Publication Analysis
Top Keywords
peptide-1 glp-1
8
glp-1 agonists
8
injectable agents
4
agents treatment
4
treatment type
4
type diabetes
4
diabetes 2-glucagon-like
4
2-glucagon-like peptide-1
4
agonists food
4
food drug
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!